Search

Displaying results 2151 - 2160 of 6074 in total
  1. Drug

    Streptococcus pneumoniae type 6A capsular polysaccharide diphtheria CRM197 protein conjugate antigen

    go.drugbank.com/drugs/DB10296
    ApprovedInvestigational

    Streptococcus pneumoniae type 6A capsular polysaccharide diphtheria CRM197 protein conjugate antigen is a sterile vaccine that contains saccharides of the capsular antigens of Streptococcus pneumoniae serotype 6a individually conjugated ...

    Mixtures: PREVENAR 13 SUSPENSION FOR INJECTION
  2. Drug

    Thenalidine

    go.drugbank.com/drugs/DB04826
    ApprovedWithdrawn

    Withdrawn from the Canadian, US, and UK markets in 1963 due to concerns involving neutropenia.

    Categories: Antihistamines for Systemic Use, Antihistamines for Topical Use
  3. Drug

    Metamizole

    go.drugbank.com/drugs/DB04817
    ApprovedInvestigationalWithdrawn

    Approvals of the NDA's for metamizole drug products were withdrawn on June 27, 1977 (see the Federal Register of June 17, 1977, 42 FR 30893).

  4. Drug

    Secobarbital

    go.drugbank.com/drugs/DB00418
    ApprovedVet approved

    Secobarbital (marketed by Eli Lilly and Company under the brand names Seconal and Tuinal) is a barbiturate derivative drug with anaesthetic, anticonvulsant, sedative and hypnotic properties. It is commonly known as quinalbarbitone in the...

  5. Drug

    NGX267

    go.drugbank.com/drugs/DB05152
    Investigational

    It is developed for the treatment of Alzheimer’s disease and has shown the potential to both reduce symptoms and slow disease progression.

  6. Drug

    Sugemalimab

    go.drugbank.com/drugs/DB16641
    ApprovedInvestigational

    [L53333] In combination with platinum-based chemotherapy, sugemalimab is a first-line treatment indicated for adult populations with metastatic non-small cell lung cancer (NSCLC) with no sensitising EGFR

  7. Drug

    Omaveloxolone

    go.drugbank.com/drugs/DB12513
    ApprovedInvestigational

    [L45424] The EMA approved this drug the following year, in February 2024, and Health Canada in March 2025 for the same condition. … [A257529] In February 2023, omaveloxolone was approved by the FDA for the treatment of Friedreich's ataxia in adults and adolescents aged 16 years and older.

  8. Drug

    Ancestim

    go.drugbank.com/drugs/DB09103
    ApprovedWithdrawn

    It was submitted to the FDA under the status of recommendation for approval with a 10 to 1 votes. … It is a 166 amino acid protein produced by E. coli with an amino acid sequence that is identical to the natural sequence predicted from human DNA sequence analysis, except for the addition of an N-terminal

  9. Drug

    Agmatine

    go.drugbank.com/drugs/DB08838
    Experimental

    The exact mechanism of action is still being investigated for all of the potential indications of agmatine. … As an experimental drug, agmatine is being studied for several indications such as cardioprotection, diabetes, decreased kidney function, neuroprotection (stroke, severe CNS injuries, epilepsy, glaucoma

  10. Drug

    Pemigatinib

    go.drugbank.com/drugs/DB15102
    ApprovedInvestigational

    This malignancy accounts for 15% to 20% of primary hepatobiliary malignancies, which account for 13% of overall cancer-related global mortality. … [A198963] The FDA-approved indication for pemigatinib was granted under accelerated approval based on the overall response rate and duration of response in pre-marketing clinical trials.